Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Forecast EPS for 2021

<< Previous

Bullboard Posts

Next >>

Post by nozzpackon Dec 06, 2021 9:25am

261 Views

Post# 34201609

Forecast EPS for 2021

Removing one time impairment costs, $0.33 cad per share for the first 3 quarters on sales of $16.4 million US.
As Q4 is the strongest quarter in the US, I see A4 net earnings in the $0.10-12 cad per share for 2021 which will result in $0.43 to $0.45 cad in net earnings for 2021 on sales of $22 million US.

This will be very close to ..again less impairments..$0.41 cad in net earnings in 2020 on sales of $21.6 million US.

So, we are now trading at just 4.5 times net earnings with $20 million cad in cash..

<< Previous

Bullboard Posts

Next >>

Canada Nickel unveils second of seven resources planned by mid-2025